查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586396

淀粉样变性治疗市场、规模、占有率、趋势、行业分析报告：按治疗、按最终用户、按地区 - 市场预测，2024-2032

Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2024-2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球淀粉样变性治疗市场预计将达到 97.9 亿美元。该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

淀粉样变性治疗市场是更广泛的医疗保健领域的重要组成部分。淀粉样变性治疗市场专注于治疗一组罕见但严重的疾病，其特征是淀粉样蛋白在各种组织和器官中异常沉积。淀粉样变性分为多种类型，包括 AL（轻链）、AA（继发性）、遗传性和野生型 ATTR（运甲状腺素蛋白淀粉样变性）。这些病症的复杂性需要多种治疗方案，从而带来显着的市场进步。

由于对疾病机制的深入瞭解和诊断技术的改进，淀粉样变性治疗市场在过去几十年中不断发展。从历史上看，淀粉样变性的治疗选择有限，通常与患者预后不良相关。然而，随着达雷妥尤单抗和他法米迪等新疗法的推出，淀粉样变性的治疗发生了显着变化。

由于认识提高、持续研究和开发以及人口老化加剧等多种因素，全球淀粉样变性治疗市场正在扩大。此外，影像和生物标记识别等诊断技术的进步正在促进早期诊断，这对于有效治疗淀粉样变性至关重要。

淀粉样变性治疗市场报告重点

在淀粉样变性治疗市场中，根据最终用途，由于对以患者为中心的治疗的偏好不断增加，预计家庭护理领域在预测期内将出现显着增长。

医院和诊所凭藉其完善的基础设施以及能够处理复杂淀粉样变性病例的专业医务人员，在 2023 年占据市场主导地位。

从治疗方式来看，化疗由于其在相关疾病（尤其是 AL 淀粉样变性）治疗方面的疗效已确立，因此将在 2023 年占据市场的主要占有率。此外，联合疗法的进步增加了对化疗的需求。

由于对 AL 淀粉样变性患者进行造血干细胞移植的认识不断提高，预计移植领域在预测期内将以强劲的速度增长。

在全球市场中，由于人口老化加剧和人们对疾病的认识不断提高，北美地区在 2023 年占据了最大的收入占有率。

由于慢性病的增加和医疗保健支出的增加，预计亚太市场在预测期内将出现显着的复合年增长率。

全球主要市场参与者包括：辉瑞公司（Johnson & Johnson Services, Inc.）；武田製药有限公司（Takeda Pharmaceutical Company Limited）；默克製药公司（Merck KGaA）；诺华公司、Ionis 製药公司、百时美施贵宝公司和安进公司

目录

第1章简介

第 2 章执行摘要

第3章研究方法

第 4 章全球淀粉样变性治疗市场洞察

  • 市场快照
  • 淀粉样变性治疗市场动态
    • 促进因素和机会
      • 诊断技术的进步正在扩大市场规模
      • 随着世界各地临床试验的增加，淀粉样变性治疗市场正在不断成长。
    • 抑制因素和课题
      • 治疗成本上升预计将阻碍市场成长。
  • PESTEL 分析
  • 淀粉样变性治疗市场趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第5章全球淀粉样变性治疗市场：依治疗分类

  • 主要发现
  • 简介
  • 化疗
  • 免疫抑制剂
  • 移植
  • 支持性护理
  • 手术
  • 其他

第 6 章全球淀粉样变性治疗市场：依最终使用者划分

  • 主要发现
  • 简介
  • 医院/诊所
  • 门诊手术中心
  • 居家照护环境
  • 其他

第7章全球淀粉样变性治疗市场：按地区

  • 主要发现
  • 简介
    • 淀粉样变性治疗市场评估：地区，2019-2032
  • 北美
    • 北美：治疗，2019-2032 年
    • 北美：依最终使用者划分，2019-2032 年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依治疗方式划分，2019-2032 年
    • 欧洲：依最终使用者划分，2019-2032 年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 欧洲其他地区
  • 亚太地区
    • 亚太地区：治疗，2019-2032 年
    • 亚太地区：依最终使用者划分，2019-2032 年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 中东/非洲
    • 中东与非洲：治疗，2019-2032 年
    • 中东和非洲：按最终用户划分，2019-2032 年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲：依处理方式划分，2019-2032 年
    • 拉丁美洲：依最终使用者划分，2019-2032 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区

第8章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协定/揭露

第9章公司简介

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Amgen Inc.
Product Code: PM5132

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others

By End User Outlook (Revenue, USD Billion, 2024-2032)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

By Regional Outlook (Revenue, USD Billion, 2024-2032)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Amyloidosis Treatment Market Insights

  • 4.1. Amyloidosis Treatment Market - Market Snapshot
  • 4.2. Amyloidosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in diagnostic technologies are driving the market size
      • 4.2.1.2. Increasing clinical trials worldwide are driving the amyloidosis treatment market.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The high cost of treatments is expected to impede market growth.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Amyloidosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Amyloidosis Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Amyloidosis Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD billion)
  • 5.4. Immunosuppressive Drugs
    • 5.4.1. Global Amyloidosis Treatment Market, by Immunosuppressive Drugs, by Region, 2019-2032 (USD billion)
  • 5.5. Transplantation
    • 5.5.1. Global Amyloidosis Treatment Market, by Transplantation, by Region, 2019-2032 (USD billion)
  • 5.6. Supportive Care
    • 5.6.1. Global Amyloidosis Treatment Market, by Supportive Care, by Region, 2019-2032 (USD billion)
  • 5.7. Surgery
    • 5.7.1. Global Amyloidosis Treatment Market, by Surgery, by Region, 2019-2032 (USD billion)
  • 5.8. Others
    • 5.8.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

6. Global Amyloidosis Treatment Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Global Amyloidosis Treatment Market, by Hospitals & Clinics, by Region, 2019-2032 (USD billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Amyloidosis Treatment Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD billion)
  • 6.5. Home Care Settings
    • 6.5.1. Global Amyloidosis Treatment Market, by Home Care Settings, by Region, 2019-2032 (USD billion)
  • 6.6. Others
    • 6.6.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

7. Global Amyloidosis Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Amyloidosis Treatment Market Assessment, By Geography, 2019-2032 (USD billion)
  • 7.3. Amyloidosis Treatment Market - North America
    • 7.3.1. North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.3.2. North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.3. Amyloidosis Treatment Market - U.S.
      • 7.3.3.1. U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.3.2. U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.4. Amyloidosis Treatment Market - Canada
      • 7.3.4.1. Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.4.2. Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.4. Amyloidosis Treatment Market - Europe
    • 7.4.1. Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.4.2. Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.3. Amyloidosis Treatment Market - UK
      • 7.4.3.1. UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.3.2. UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.4. Amyloidosis Treatment Market - France
      • 7.4.4.1. France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.4.2. France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.5. Amyloidosis Treatment Market - Germany
      • 7.4.5.1. Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.5.2. Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.6. Amyloidosis Treatment Market - Italy
      • 7.4.6.1. Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.6.2. Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.7. Amyloidosis Treatment Market - Spain
      • 7.4.7.1. Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.7.2. Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.8. Amyloidosis Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.8.2. Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.9. Amyloidosis Treatment Market - Russia
      • 7.4.9.1. Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.9.2. Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.10. Amyloidosis Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.10.2. Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.5. Amyloidosis Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.5.2. Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.3. Amyloidosis Treatment Market - China
      • 7.5.3.1. China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.3.2. China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.4. Amyloidosis Treatment Market - India
      • 7.5.4.1. India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.4.2. India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.5. Amyloidosis Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.5.2. Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.6. Amyloidosis Treatment Market - Japan
      • 7.5.6.1. Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.6.2. Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.7. Amyloidosis Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.7.2. Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.8. Amyloidosis Treatment Market - South Korea
      • 7.5.8.1. South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.8.2. South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.9. Amyloidosis Treatment Market - Australia
      • 7.5.9.1. Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.9.2. Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.10. Amyloidosis Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.10.2. Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.6. Amyloidosis Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.6.2. Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.3. Amyloidosis Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.3.2. Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.4. Amyloidosis Treatment Market - UAE
      • 7.6.4.1. UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.4.2. UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.5. Amyloidosis Treatment Market - Israel
      • 7.6.5.1. Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.5.2. Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.6. Amyloidosis Treatment Market - South Africa
      • 7.6.6.1. South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.6.2. South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.7. Amyloidosis Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.7.2. Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.7. Amyloidosis Treatment Market - Latin America
    • 7.7.1. Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.7.2. Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.3. Amyloidosis Treatment Market - Mexico
      • 7.7.3.1. Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.3.2. Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.4. Amyloidosis Treatment Market - Brazil
      • 7.7.4.1. Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.4.2. Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.5. Amyloidosis Treatment Market - Argentina
      • 7.7.5.1. Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.5.2. Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.6. Amyloidosis Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.6.2. Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Johnson & Johnson Services, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GSK plc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Takeda Pharmaceutical Company Limited
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Alnylam Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Merck KGaA
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. F. Hoffmann-La Roche Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Ionis Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Bristol-Myers Squibb Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Amgen Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development

List of Tables:

  • Table 1 Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 2 Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 3 North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 4 North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 5 U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 6 U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 7 Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 8 Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 9 Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 10 Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 11 UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 12 UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 13 France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 14 France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 15 Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 16 Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 17 Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 18 Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 19 Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 20 Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 21 Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 22 Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 23 Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 24 Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 25 Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 26 Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 27 Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 28 Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 29 China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 30 China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 31 India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 32 India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 33 Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 34 Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 35 Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 36 Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 37 Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 38 Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 39 South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 40 South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 41 Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 42 Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 43 Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 44 Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 45 Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 46 Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 47 Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 48 Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 49 UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 50 UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 51 Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 52 Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 53 South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 54 South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 55 Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 56 Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 57 Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 58 Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 59 Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 60 Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 61 Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 62 Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 63 Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 64 Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 65 Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 66 Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • List of Figures:
  • Figure 1. Global Amyloidosis Treatment Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Amyloidosis Treatment Market, by Treatment, 2023 & 2032 (USD billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Amyloidosis Treatment Market, by End-use, 2023 & 2032 (USD billion)